Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMasonic Cancer Center, University of Minnesota

About this trial

This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic catheter into the thoracic spine to administer anesthetic and pain medication, such as bupivacaine and hydromorphone, to treat pain in the thoracic and upper abdominal areas during and after surgery. Epidurals have been successfully used to treat pain after surgery, however, it does have a risk of low blood pressure which may limit the use in the thoracic approach. Rectus sheath blocks with liposomal bupivacaine may be as effective as TEA in reducing pain in patients following a pancreatoduodenectomy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients, age 18 and older, undergoing open pancreaticoduodenectomy at the University of Minnesota will be included in the study

Disqualifiers

Patients with contraindication to block placement (coagulopathy, local anesthetic allergy, infection)

Patients with chronic opioid use (at least 30 milligram morphine equivalents [MME] for 3 or more weeks leading up to surgery)

Patients unable to understand the quality of recovery survey intellectual barriers. This will be determined by the primary investigator/attending anesthesiologist's discretion

Patient refusal and those who have opted out of research

Trial design

Design model

Parallel

Treatments tested in this trial

  • Bupivacaine

    Drug

    Given via epidural and injection

  • Hydromorphone

    Drug

    Given via epidural

  • Iopamidol

    Drug

    Given via epidural

  • Liposomal Bupivacaine

    Drug

    Given injection

  • Medical Chart Review

    Other intervention

    Ancillary studies

  • Questionnaire Administration

    Other intervention

    Ancillary studies

  • Thoracic Epidural Analgesia

    Drug

    Undergo thoracic epidural placement

  • Ultrasound Imaging

    Procedure/Surgery

    Undergo ultrasound

  • X-Ray Imaging

    Procedure/Surgery

    Undergo x-ray

Treatment groups

78 Participants
are divided into 2 treatment groups
Group A: Group E (TEA)Experimental treatment 7 interventions
Group B: Group RS (rectus sheath block)Experimental treatment 5 interventions

Trial outcomes

Primary outcomes

1

Milligram morphine equivalents (MME)

Opioid consumption will be evaluated as a non-inferiority hypothesis using a two-sample t-test to compare the groups, with the conclusion of statistical significance being drawn from the corresponding confidence interval for the differences in mean MMEs between groups.

Time frame
Up to 96 hours after open pancreatoduodenectomy

Secondary outcomes

1

Pain scores

Pain scores at rest and with movement will be assessed using a numeric rating scale pain scores where 0 is no pain and 10 is worst pain.

Time frame
At 24, 48, 72 and 96 hours
2

Hospital length of stay

Average hospital length of stay

Time frame
Up to 7 days after surgery
3

Opioid consumption

Average Opioid consumption (milligrams)

Time frame
96 hours
4

Time to return of bowel function

Average time to return of bowel function will be measured by first oral intake.

Time frame
Up to 7 days after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Masonic Cancer Center, University of Minnesota

Lead sponsor

National Cancer Institute (NCI)

Collaborator